Based out of Zurich, Oviva is a digital health company that helps people with conditions such as obesity, diabetes, and food allergies improve their health with medical, nutritional therapy from professional dietitians.
Recently, the company has raised $21 million (approx €19 million) in Series B funding led by MTIP with participation from new investor Earlybird and existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures and Partech.
As per the company claims, the new capital will be used to develop the technology further and expand in Europe to serve more people. To date, the startup has raised around $34 million (approx €30.4 million). Christoph Kausch from MTIP and Rainer Christine from Earlybird will be joining Oviva’s Board of Directors.
Kai Eberhardt, CEO and Co-founder of Oviva, added:
“The new financing allows us to roll out our uniquely effective solution to large patient populations rapidly across Europe and further develop the underlying technology to better address patients’ unmet needs.”
Founded in 2014 by Kai Eberhardt, Manuel Baumann, Mark Jenkins, Oviva has claimed to treat over 90,000 patients in the last three years across various countries, including the U.K., Germany, France, Switzerland, and the UAE.
This Swiss startup has developed unique, personalised behavior change programmes that combine our smartphone app and learning portal to support dietitian-led behavior change for conditions such as type 2 diabetes and complex obesity.
Lucy Jones, Clinical Director of Oviva, commented:
“Behaviour change is the safest and most cost-effective way of preventing and managing diet-related health conditions including Type 2 diabetes. Our technology empowers patients to take a leading role in managing their health, improves compliance and outcomes.”
Their approach allows patients to achieve a better health outcome without having to attend clinic appointments while saving health systems significant sums by preventing the development of complications related to these health conditions.
Christoph Ruedig, the partner at AlbionVC, explained:
“Despite compelling evidence that digital treatments improve patient access and outcomes significantly while reducing costs for health systems, Europe is investing a fraction compared to the US in this area. We’re excited to continue to support Oviva’s accelerated roll out across Europe.”
Main image credits: Oviva
Stay tuned to Silicon Canals for more European technology news
